These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 11829449)

  • 1. The current management of diabetic dyslipidaemia.
    Betteridge DJ
    Acta Diabetol; 2001; 38 Suppl 1():S15-9. PubMed ID: 11829449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What does the future hold for diabetic dyslipidaemia?
    Crespin SR
    Acta Diabetol; 2001; 38 Suppl 1():S21-6. PubMed ID: 11829450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins.
    Papadakis JA; Milionis HJ; Press M; Mikhailidis DP
    J Diabetes Complications; 2001; 15(4):211-26. PubMed ID: 11457674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic dyslipidaemia: insights for optimizing patient management.
    Vergès B
    Curr Med Res Opin; 2005; 21 Suppl 1():S29-40. PubMed ID: 15811197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
    García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
    Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic dyslipidaemia.
    Betteridge DJ
    Diabetes Obes Metab; 2000 Mar; 2 Suppl 1():S31-6. PubMed ID: 11225757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current, new and future treatments in dyslipidaemia and atherosclerosis.
    Chong PH; Bachenheimer BS
    Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: an update.
    Hovens MM; Tamsma JT; Beishuizen ED; Huisman MV
    Drugs; 2005; 65(4):433-45. PubMed ID: 15733008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
    Keating GM; Ormrod D
    Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic dyslipidaemia: current treatment recommendations.
    Best JD; O'Neal DN
    Drugs; 2000 May; 59(5):1101-11. PubMed ID: 10852642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.
    Woodman RJ; Chew GT; Watts GF
    Drugs; 2005; 65(1):31-74. PubMed ID: 15610050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive lipid-lowering strategy in patients with diabetes mellitus.
    Kanters SD; Algra A; de Bruint TW; Erkelens DW; Banga JD
    Diabet Med; 1999 Jun; 16(6):500-8. PubMed ID: 10391399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of dyslipidemia in adults with diabetes.
    Haffner SM
    Diabetes Care; 1998 Jan; 21(1):160-78. PubMed ID: 9538988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidaemia in type 2 diabetes mellitus: bad for the heart.
    Katsiki N; Tentolouris N; Mikhailidis DP
    Curr Opin Cardiol; 2017 Jul; 32(4):422-429. PubMed ID: 28362666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H; Goyal RK
    Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.